Mechanisms linking periodontitis and diabetes

Background + Aims

• Gut bacteria produce substances that can influence the immune system, including butyrate, a short-chain fatty acid commonly produced when bacteria break down dietary fibre.
• 2 types of immune cells are relevant:
  • Treg cells help control inflammation and protect healthy tissues,
  • Th17 cells help fight infection but can contribute to tissue damage when excessively active.
• Maintaining an appropriate Treg/Th17 balance helps the body defend against infection without causing excessive damage to its own tissues.
• This study aimed to:
  • Investigate whether butyrate reduces periodontal damage by restoring the balance between Treg and Th17 cells.

Materials + Methods

• A mouse model of diabetes-associated periodontitis was established using low-dose streptozotocin to induce type-1-like diabetes, followed by ligature-induced periodontitis.

• Outcomes assessed included alveolar bone loss (micro-CT, histology and osteoclast staining), Treg and Th17 frequencies in lymph nodes and spleen, colonic mucus barrier integrity, faecal microbiota composition and short-chain fatty acid concentrations in stool and serum.

• To test microbial causality, faecal microbiota transplantation (FMT) was performed from control or diabetic periodontitis donors into antibiotic-pretreated recipient mice, which were then subjected to periodontitis induction.

• To test therapeutic potential, diabetic periodontitis mice received oral butyrate for 3-weeks. Complementary in-vitro polarisation assays examined the underlying immunological mechanism.

Results

• Mice with diabetes-associated periodontitis showed a pronounced increase in Th17 cells alongside elevated pro-inflammatory cytokines. Treg frequencies also rose, which the authors interpret as a compensatory response consistent with prior observations in type 1 diabetes rather than as effective immune regulation.

• Compromised gut barrier and altered microbiota. Colonic mucin production was reduced, indicating impaired mucus-barrier integrity. The gut microbial community was restructured (gut dysbiosis), with a reduction in short-chain fatty acid–producing and anti-inflammatory taxa and enrichment of pro-inflammatory genera.

• Short chain fatty acid findings revealed faecal acetate was significantly reduced. Reductions in faecal butyrate and propionate showed a downward trend but did not reach statistical significance. Serum butyrate was significantly reduced.

• Faecal microbiota transplantation aggravated disease. Recipients of microbiota from diabetic periodontitis donors developed more severe periodontal bone loss, a weakened colonic mucus barrier, reduced Treg and increased Th17 frequencies, and lower faecal and serum butyrate — confirming that the altered microbiota was a causal contributor rather than a bystander.

• Butyrate supplementation was protective. Oral butyrate significantly reduced alveolar bone loss and osteoclast numbers, restored anti-inflammatory cytokine levels, increased Treg and reduced Th17 frequencies, and improved colonic mucus integrity. Mechanistically, butyrate enhanced global histone H3 acetylation and suppressed STAT3 phosphorylation, consistent with HDAC inhibition promoting Treg differentiation while limiting Th17 development.

Limitations

• The streptozotocin-induced model does not fully capture the complexity of human diabetes, particularly type 2 diabetes, and cannot establish clinical effectiveness.

• The non-significant reduction in faecal butyrate should not be characterised as clear evidence of butyrate deficiency, although the reduction in serum butyrate was statistically significant.

• Improvement following supplementation does not, by itself, establish that insufficient butyrate caused the disease.

• The optimal therapeutic dose has not been determined, and excessive short-chain fatty acid exposure may aggravate certain inflammatory conditions.

• Appropriate dosing, safety, durability of benefit and added value alongside standard periodontal therapy require investigation in humans.

Conclusion

• The findings suggest that substances produced by gut bacteria may influence gum health by helping regulate inflammation.
• They support further research into butyrate, but do not establish butyrate supplements as a recommended treatment for people with diabetes and periodontitis.